Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 18 of 51 for:    "Hypogonadism" | "Estrogens"

A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02651688
Recruitment Status : Completed
First Posted : January 11, 2016
Results First Posted : June 14, 2019
Last Update Posted : June 27, 2019
Sponsor:
Information provided by (Responsible Party):
Repros Therapeutics Inc.

Brief Summary:
The purpose of this study is to compare the effects of 12 months of treatment with enclomiphene 12.5 mg, 25 mg, or placebo capsules on body composition and metabolic parameters in overweight men with acquired hypogonadotropic hypogonadism [confirmed morning testosterone (T) ≤300 ng/dL] following a 6 month diet and 15 month exercise program.

Condition or disease Intervention/treatment Phase
Acquired Hypogonadotropic Hypogonadism Obesity Drug: Placebo Drug: Enclomiphene Phase 2

Detailed Description:
To compare the effects of 12 months of treatment with enclomiphene 12.5 mg, 25 mg, or placebo capsules on body composition and metabolic parameters in overweight men with acquired hypogonadotropic hypogonadism (confirmed morning T≤300 ng/dL) following a 6 month diet and 15 month exercise program. Participants must not have been treated with testosterone products in the 6 months prior to the study and must not ever have used testosterone products for a year or longer.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind, Placebo-Controlled, Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene
Actual Study Start Date : January 11, 2016
Actual Primary Completion Date : May 2, 2017
Actual Study Completion Date : May 2, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Enclomiphene 12.5 mg
Enclomiphene 12.5 milligram (mg) capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
Drug: Enclomiphene
Enclomiphene capsule daily in the morning with approximately 8 ounces of water for up to 12 months.

Experimental: Enclomiphene 25 mg
Enclomiphene 25 mg capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
Drug: Enclomiphene
Enclomiphene capsule daily in the morning with approximately 8 ounces of water for up to 12 months.

Placebo Comparator: Placebo
One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
Drug: Placebo
One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months.




Primary Outcome Measures :
  1. Change From Baseline in Lean Body Mass (LBM) at Week 48 [ Time Frame: Baseline (Day 0) to Week 48 ]
    LBM was assessed using dual-energy X-ray absorptiometry (DXA). A positive change from Baseline indicates improvement.

  2. Change From Baseline in Body Strength (Chest Press Weight) at Week 48 [ Time Frame: Baseline (Day 0) to Week 48 ]
    Body strength was assessed from maximum chest and leg press weight achieved, using an inclined plane leg press and vertical chest press. A positive change from Baseline indicates improvement.

  3. Change From Baseline in Body Strength (Leg Press Weight) at Week 48 [ Time Frame: Baseline (Day 0) to Week 48 ]
    Body strength was assessed from maximum chest and leg press weight achieved, using an inclined plane leg press and vertical chest press. A positive change from Baseline indicates improvement.

  4. Change From Baseline in Blood Luteinizing Hormone (LH) Level at Week 48 [ Time Frame: Baseline (Day 0) to Week 48 ]
    A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter LH measured in milli-International Units per milliliter (mIU/mL). A positive change from Baseline indicates improvement.

  5. Change From Baseline in Blood Testosterone (T) Level at Week 48 [ Time Frame: Baseline (Day 0) to Week 48 ]
    A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter T. A positive change from Baseline indicates improvement.

  6. Change From Baseline in Blood Dihydrotestosterone (DHT) Level at Week 48 [ Time Frame: Baseline (Day 0) to Week 48 ]
    A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter DHT. A positive change from Baseline indicates improvement.

  7. Change From Baseline in Blood Estradiol (E2) Level at Week 48 [ Time Frame: Baseline (Day 0) to Week 48 ]
    A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter E2. A positive change from Baseline indicates improvement.

  8. Change From Baseline in Ratio of Testosterone: Estradiol (T:E2) at Week 48 [ Time Frame: Baseline (Day 0) to Week 48 ]
    The T:E2 ratio was calculated as the value of T/value of E2 using the same units. A positive change from Baseline indicates improvement.

  9. Change From Baseline in Ratio of Dihydrotestosterone: Testosterone (DHT:T) at Week 48 [ Time Frame: Baseline (Day 0) to Week 48 ]
    The DHT:T ratio was calculated as the value of DHT/value of T using the same units. A negative change from Baseline indicates improvement.

  10. Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 48 [ Time Frame: Baseline (Day 0) to Week 48 ]
    A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter HbA1c. A negative change from Baseline indicates improvement.

  11. Change From Baseline in Blood Glucose Level at Week 48 [ Time Frame: Baseline (Day 0) to Week 48 ]
    A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter Glucose. A negative change from Baseline indicates improvement.

  12. Change From Baseline in Blood C-reactive Protein (CRP) Level at Week 48 [ Time Frame: Baseline (Day 0) to Week 48 ]
    A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter CRP. A negative change from Baseline indicates improvement.

  13. Change From Baseline in Blood Interleukin-6 (IL-6) Level at Week 48 [ Time Frame: Baseline (Day 0) to Week 48 ]
    A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter IL-6. A negative change from Baseline indicates improvement.

  14. Change From Baseline in Blood Tumor Necrosis Factor Alpha (TNF-α) Level at Week 48 [ Time Frame: Baseline (Day 0) to Week 48 ]
    A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter TNF-α . A negative change from Baseline indicates improvement.

  15. Change From Baseline in Blood Leptin Level at Week 48 [ Time Frame: Baseline (Day 0) to Week 48 ]
    A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter leptin. A negative change from Baseline indicates improvement.

  16. Change From Baseline in Homeostatic Model of Assessment - Insulin Resistance (HOMA-IR) at Week 48 [ Time Frame: Baseline (Day 0) to Week 48 ]
    The HOMA-IR is the product of the blood Glucose and Insulin levels, divided by a constant. HOMA-IR is expressed as the following: HOMA-IR = fasting serum insulin (μU/mL) × fasting plasma glucose (mmol/L)/22.5. A negative change from Baseline indicates improvement.

  17. Change From Baseline in Blood Quantose-Insulin Resistance (IR) Score at Week 48 [ Time Frame: Baseline (Day 0) to Week 48 ]
    Quantose-IR is a laboratory-developed test that assesses insulin resistance. Quantose-IR score is based on a linear regression algorithm utilizing the quantitative measures (natural log transformed) of alpha-hydroxybutyrate, oleate, linoleoylglycerophosphocholine and insulin and was designed to estimate the natural log of insulin-induced glucose infusion rate normalized by whole body mass. The algorithm score is converted to the Quantose-IR score within a range of 1-120 by an arithmetic calculation where higher scores denote greater insulin resistance. A negative change from Baseline indicates improvement.

  18. Change From Baseline in Body Mass Index (BMI) at Week 48 [ Time Frame: Baseline (Day 0) to Week 48 ]
    BMI is calculated as weight (kg)/height(cm^2). A negative change from Baseline indicates improvement.

  19. Change From Baseline in Waist Circumference at Week 48 [ Time Frame: Baseline (Day 0) to Week 48 ]
    A negative change from Baseline indicates improvement.

  20. Change From Baseline in Weight at Week 48 [ Time Frame: Baseline (Day 0) to Week 48 ]
    A negative change from Baseline indicates improvement.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Overweight (Body Mass Index (BMI) 30 to 42 (kg/m^2) inclusive) males age 18 to 60 inclusive.
  • Waist circumference ≥ 40 inches (101.6 cm).
  • Previously or concurrently diagnosed as having secondary hypogonadism.
  • Must have 2 morning testosterone assessments at Visit 1, collected before 10 AM, 2-4 days apart, and both of which must be ≤ 300 (ng/dL).
  • Luteinizing hormone (LH) >1.4 and < 9.4 milli International units per milliliter (mIU/mL) (at Visit 1 only).
  • Glycated hemoglobin A1c (HbA1c) ≤7.5.
  • Stable weight for last 3 months (+/- 10 pounds).
  • Participant lives or works within 10 miles of the gym that will be used for the study.
  • Must be fit enough to participate in the fitness program.
  • Ability to complete the study in compliance with the protocol requirements.
  • Ability to understand and provide written informed consent.

Exclusion Criteria:

  • Any use of testosterone products (injectable, pelleted, transdermal or sublingual) in the 6 months prior to the study or any prior use of testosterone products for 12 months or longer at any time.
  • Use of testosterone, Clomid, 5α-reductase inhibitors, human chorionic gonadotropin (hCG), androgen, estrogen, anabolic steroid, dehydroepiandrosterone (DHEA), or herbal hormone products during the study.
  • Use of Clomid in the past year.
  • Known hypersensitivity to Clomid.
  • Allergy to soy, peanuts or latex.
  • Chronic use of glucocorticoids (chronic use of inhaled or topical glucocorticoids is acceptable).
  • History of drug abuse or chronic narcotic use including methadone.
  • A recent history of alcoholism or illegal substance or steroid abuse (<2 years) or presence of moderate alcohol use (>21 drinks per week).
  • Use of an investigational drug or product, or participation in a drug or medical device research study within 30 days prior to receiving study medication.
  • A hematocrit >54%.
  • Presence or known history of hyperprolactinemia with or without a tumor (prolactin >20 ng/mL).
  • Current or history of prostate cancer or a suspicion of prostate disease unless ruled out by prostate biopsy, or a prostate specific antigen (PSA)>3.6.
  • Current or history of breast cancer.
  • Uncontrolled hypertension based on the Investigator's assessment at screening.
  • History of bulimia nervosa or binge eating.
  • Participant has (had) a lap band or undergone gastric bypass surgery.
  • Participant has celiac disease or gluten intolerance.
  • Participant has Type I diabetes.
  • Participant has any condition which in the opinion of the investigator would interfere with the participant's ability to provide informed consent, comply with study instructions, possibly confound interpretation of study results, or endanger the participant if he took part in the study.
  • Enrolled and randomized (if applicable) in a previous enclomiphene study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02651688


Locations
Layout table for location information
United States, New York
Albany, New York, United States, 12208
Garden City, New York, United States, 11530
United States, Rhode Island
Providence, Rhode Island, United States, 02903
United States, Utah
Riverton, Utah, United States, 84065
United States, Virginia
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
Repros Therapeutics Inc.
Investigators
Layout table for investigator information
Study Director: Anna Chan Allergan
  Study Documents (Full-Text)

Documents provided by Repros Therapeutics Inc.:
Statistical Analysis Plan  [PDF] July 29, 2016
Study Protocol  [PDF] December 9, 2016


Layout table for additonal information
Responsible Party: Repros Therapeutics Inc.
ClinicalTrials.gov Identifier: NCT02651688     History of Changes
Other Study ID Numbers: ZA-205
First Posted: January 11, 2016    Key Record Dates
Results First Posted: June 14, 2019
Last Update Posted: June 27, 2019
Last Verified: June 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypogonadism
Estrogen Antagonists
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Gonadal Disorders
Endocrine System Diseases
Enclomiphene
Clomiphene
Zuclomiphene
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents